Treatment Adherence to Nucleos(t)ide Analogs in Chinese Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma: A Single-Center Cross-Sectional Study

Overview

Journal Patient Prefer Adherence

Date 2021 Aug 19

PMID 34408406

Citations 1

Authors

YueYue Li

Anni Chen

Hui Wang

Lu Han

Rong Wang

GuoQing Zhang

Yongfang Yuan

Affiliations

Soon will be listed here.

Abstract

Purpose: Chronic hepatitis B virus (HBV) infection is a crucial risk factor in the occurrence and development of hepatocellular carcinoma (HCC). Antiviral therapy is very important for patients with HBV-related HCC. To maintain undetectable level of HBV DNA, patients must take nucleos(t)ide analogues (NUCs) appropriately and regularly. We explored the adherence of Chinese patients with HBV-related HCC to antiviral treatment.

Patients And Methods: One-hundred and eighty-one patients were included in a cross-sectional study between August 2020 and February 2021. A structured questionnaire was used to interview patients, and a form was applied to collect data from electronic medical records. Medication adherence was measured using a visual analog scale. Data of the adherent group and non-adherent group were compared using Student's -test and the chi-square test. Multivariate logistic regression analysis was employed to explore independent risk factors that affected adherence behavior.

Results: High adherence was reported in 46.4% of patients with HBV-related HCC. Patients with high adherence were more likely to be women (P = 0.02), shun alcohol (P = 0.01), take NUCs other than entecavir (P = 0.04), and pay attention to their titer of HBV DNA (P = 0.05). Sex, alcohol consumption, and taking entecavir were independent risk factors for low adherence (P < 0.05). The prevalence of virological breakthrough was lower in patients who adhered to NUC therapy than in those who did not, but the difference was not significant (P = 0.31).

Conclusion: The adherence of patients with HBV-related HCC to NUC therapy was low. More attention should be paid to adherence of antiviral therapy in patients with HBV-related HCC.

Citing Articles

Shared-care models are highly effective and cost-effective for managing chronic hepatitis B in China: reinterpreting the primary care and specialty divide.

Zhang L, Liu H, Zou Z, Su S, Ong J, Ji F Lancet Reg Health West Pac. 2023; 35:100737.

PMID: 37424676 PMC: 10326699. DOI: 10.1016/j.lanwpc.2023.100737.

References

Chotiyaputta W, Peterson C, Ditah F, Goodwin D, Lok A . Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B. J Hepatol. 2010; 54(1):12-8. DOI: 10.1016/j.jhep.2010.06.016. View

Burton M, Voluse A, Patel A, Konkle-Parker D . Measuring Adherence to Hepatitis C Direct-Acting Antiviral Medications: Using the VAS in an HCV Treatment Clinic. South Med J. 2018; 111(1):45-50. DOI: 10.14423/SMJ.0000000000000750. View

Peng J, Yin J, Cai S, Yu T, Zhong C . Factors associated with adherence to nucleos(t)ide analogs in chronic hepatitis B patients: results from a 1-year follow-up study. Patient Prefer Adherence. 2015; 9:41-5. PMC: 4293917. DOI: 10.2147/PPA.S71510. View

Herbst D, Reddy K . Risk factors for hepatocellular carcinoma. Clin Liver Dis (Hoboken). 2019; 1(6):180-182. PMC: 6499296. DOI: 10.1002/cld.111. View

Caro J, Salas M, Speckman J, Raggio G, Jackson J . Persistence with treatment for hypertension in actual practice. CMAJ. 1999; 160(1):31-7. PMC: 1229943. View

El-Serag H . Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012; 142(6):1264-1273.e1. PMC: 3338949. DOI: 10.1053/j.gastro.2011.12.061. View

Hilleret M, Larrat S, Stanke-Labesque F, Leroy V . Does adherence to hepatitis B antiviral treatment correlate with virological response and risk of breakthrough?. J Hepatol. 2011; 55(6):1468-9. DOI: 10.1016/j.jhep.2011.04.006. View

van Vlerken L, Arends P, Lieveld F, Arends J, Brouwer W, Siersema P . Real life adherence of chronic hepatitis B patients to entecavir treatment. Dig Liver Dis. 2015; 47(7):577-83. DOI: 10.1016/j.dld.2015.03.024. View

Bjelland I, Dahl A, Haug T, Neckelmann D . The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res. 2002; 52(2):69-77. DOI: 10.1016/s0022-3999(01)00296-3. View

10.

Sogni P, Carrieri M, Fontaine H, Mallet V, Vallet-Pichard A, Trabut J . The role of adherence in virological suppression in patients receiving anti-HBV analogues. Antivir Ther. 2012; 17(2):395-400. DOI: 10.3851/IMP1944. View

11.

Chen W, Sun K, Zheng R, Zeng H, Zhang S, Xia C . Cancer incidence and mortality in China, 2014. Chin J Cancer Res. 2018; 30(1):1-12. PMC: 5842223. DOI: 10.21147/j.issn.1000-9604.2018.01.01. View

12.

Manolakopoulos S, Striki A, Papastergiou V, Perlepe N, Zisimopoulos K, Papazoglou A . Persistence and adherence to nucleos(t)ide analogues in chronic hepatitis B: a multicenter cohort study. Eur J Gastroenterol Hepatol. 2019; 32(5):635-641. DOI: 10.1097/MEG.0000000000001558. View

13.

Marentette M, Gerth W, Billings D, Zarnke K . Antihypertensive persistence and drug class. Can J Cardiol. 2002; 18(6):649-56. View

14.

Arzumanyan A, Reis H, Feitelson M . Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer. 2013; 13(2):123-35. DOI: 10.1038/nrc3449. View

15.

Ha N, Ha N, Garcia R, Trinh H, Chaung K, Nguyen H . Medication nonadherence with long-term management of patients with hepatitis B e antigen-negative chronic hepatitis B. Dig Dis Sci. 2011; 56(8):2423-31. DOI: 10.1007/s10620-011-1610-5. View

16.

Nguyen V, Law M, Dore G . Hepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burden. J Viral Hepat. 2009; 16(7):453-63. DOI: 10.1111/j.1365-2893.2009.01117.x. View

17.

Kane S, Cohen R, Aikens J, Hanauer S . Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol. 2001; 96(10):2929-33. DOI: 10.1111/j.1572-0241.2001.04683.x. View

18.

Giang L, Selinger C, Lee A . Evaluation of adherence to oral antiviral hepatitis B treatment using structured questionnaires. World J Hepatol. 2012; 4(2):43-9. PMC: 3295851. DOI: 10.4254/wjh.v4.i2.43. View

19.

Zhang Q, Li X, Qiao S, Shen Z, Zhou Y . Comparing self-reported medication adherence measures with hair antiretroviral concentration among people living with HIV in Guangxi, China. AIDS Res Ther. 2020; 17(1):8. PMC: 7053048. DOI: 10.1186/s12981-020-00265-4. View

20.

Anand B, Currie S, Dieperink E, Bini E, Shen H, Ho S . Alcohol use and treatment of hepatitis C virus: results of a national multicenter study. Gastroenterology. 2006; 130(6):1607-16. DOI: 10.1053/j.gastro.2006.02.023. View